| Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer M Santimaria, G Moscatelli, GL Viale, L Giovannoni, G Neri, F Viti, ... Clinical Cancer Research 9 (2), 571-579, 2003 | 396 | 2003 |
| Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis F Viti, L Tarli, L Giovannoni, L Zardi, D Neri Cancer research 59 (2), 347-352, 1999 | 313 | 1999 |
| Expression of the oncofetal ED-B–containing fibronectin isoform in hematologic tumors enables ED-B–targeted 131I-L19SIP radioimmunotherapy in Hodgkin … S Sauer, PA Erba, M Petrini, A Menrad, L Giovannoni, C Grana, B Hirsch, ... Blood, The Journal of the American Society of Hematology 113 (10), 2265-2274, 2009 | 197 | 2009 |
| The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced … M Johannsen, G Spitaleri, G Curigliano, J Roigas, S Weikert, ... European journal of cancer 46 (16), 2926-2935, 2010 | 194 | 2010 |
| A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma TK Eigentler, B Weide, F de Braud, G Spitaleri, A Romanini, A Pflugfelder, ... Clinical Cancer Research 17 (24), 7732-7742, 2011 | 175 | 2011 |
| A strategy for the isolation of catalytic activities from repertoires of enzymes displayed on phage S Demartis, A Huber, F Viti, L Lozzi, L Giovannoni, P Neri, G Winter, ... Journal of molecular biology 286 (2), 617-633, 1999 | 172 | 1999 |
| Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study R Danielli, R Patuzzo, AM Di Giacomo, G Gallino, A Maurichi, A Di Florio, ... Cancer immunology, immunotherapy 64, 999-1009, 2015 | 153 | 2015 |
| Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy J Marlind, M Kaspar, E Trachsel, R Sommavilla, S Hindle, C Bacci, ... Clinical Cancer Research 14 (20), 6515-6524, 2008 | 144 | 2008 |
| Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia KL Gutbrodt, C Schliemann, L Giovannoni, K Frey, T Pabst, W Klapper, ... Science translational medicine 5 (201), 201ra118-201ra118, 2013 | 133 | 2013 |
| Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours G Spitaleri, R Berardi, C Pierantoni, T De Pas, C Noberasco, C Libbra, ... Journal of cancer research and clinical oncology 139, 447-455, 2013 | 111 | 2013 |
| Isolated limb perfusion with the tumor‐targeting human monoclonal antibody–cytokine fusion protein L19‐TNF plus melphalan and mild hyperthermia in patients with locally … F Papadia, V Basso, R Patuzzo, A Maurichi, A Di Florio, L Zardi, E Ventura, ... Journal of surgical oncology 107 (2), 173-179, 2013 | 108 | 2013 |
| The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity T Hemmerle, P Probst, L Giovannoni, AJ Green, T Meyer, D Neri British journal of cancer 109 (5), 1206-1213, 2013 | 98 | 2013 |
| Intralesional treatment of stage III metastatic melanoma patients with L19–IL2 results in sustained clinical and systemic immunologic responses B Weide, TK Eigentler, A Pflugfelder, H Zelba, A Martens, G Pawelec, ... Cancer immunology research 2 (7), 668-678, 2014 | 89* | 2014 |
| Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study GL Poli, C Bianchi, G Virotta, A Bettini, R Moretti, E Trachsel, G Elia, ... Cancer immunology research 1 (2), 134-143, 2013 | 83 | 2013 |
| Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening L Giovannoni, F Viti, L Zardi, D Neri Nucleic Acids Research 29 (5), e27-e27, 2001 | 80 | 2001 |
| Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies PA Erba, M Sollini, E Orciuolo, C Traino, M Petrini, G Paganelli, ... Journal of nuclear medicine 53 (6), 922-927, 2012 | 73 | 2012 |
| Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients DA Heuveling, R de Bree, DJ Vugts, MC Huisman, L Giovannoni, ... Journal of Nuclear Medicine 54 (3), 397-401, 2013 | 61 | 2013 |
| The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic … C Catania, M Maur, R Berardi, A Rocca, AMD Giacomo, G Spitaleri, ... Cell adhesion & migration 9 (1-2), 14-21, 2015 | 57 | 2015 |
| Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation C Schliemann, KL Gutbrodt, A Kerkhoff, M Pohlen, S Wiebe, G Silling, ... Cancer immunology research 3 (5), 547-556, 2015 | 53* | 2015 |
| A phase IB clinical trial with Dekavil (F8-IL10), an immunoregulatory ‘armed antibody’for the treatment of rheumatoid arthritis, used in combination wiIh methotrexate M Galeazzi, L Bazzichi, GD Sebastiani, D Neri, E Garcia, N Ravenni, ... Isr Med Assoc J 16 (10), 666, 2014 | 52 | 2014 |
zardi lucianoCEO and President sirius-biotechEmail verificata su sirius-biotech.com
